Also, VitD treatment ameliorated hepatic inflammation and steatosis in the NAFLD group by decreasing the expression of SREBP-1-c and increasing the expression of PPAR-α. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.